Targeted inhibition of the checkpoint molecule programmed cell death 1 (PD-1) can activate tumor-specific T cells45 while enhancing PD-1 activity is expected to suppress autoreactive T cells and reduce autoimmune disease symptoms26. Here, PDCD1 is linked to autoimmune disease.